Sarcopenic obesity in cirrhosis—The confluence of 2 prognostic titans. (25th May 2018)

• Record Type: Journal Article
• Authors: Eslamparast, Tannaz; Montano‐Loza, Aldo J.; Raman, Maitreyi; Tandon, Puneeta
• Is Part Of: Liver international. Volume 38:Number 10(2018)
• Page Start: 1706
• Page End: 1717
• Publication Date: 2018-05-25
• Subjects: cirrhosis -- muscle mass loss -- myosteatosis -- sarcopenic obesity; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.13876
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Sarcopenia and obesity are 2 major health conditions with a growing prevalence in cirrhosis. The concordance of these 2 conditions, sarcopenic obesity, is associated with higher rates of mortality and impact on the metabolic profile and physical function than either condition alone. To date, there is little consensus surrounding the diagnostic criteria for sarcopenia, obesity or as a result, sarcopenic obesity in patients with cirrhosis. Cross‐sectional imaging, although the most accurate diagnostic technique, has practical limitations for routine use in clinical practice. Management strategies are focused on increasing muscle mass and strength. The present review provides an overview of the diagnosis, pathophysiology, prognostic implications and management strategies available for sarcopenic obesity in cirrhosis. We also discuss the associated condition myosteatosis, the pathological accumulation of fat in skeletal muscle. Much work needs to be done to advance both clinical care and research in this area. Future directions require consensus definitions for sarcopenia, obesity and sarcopenic obesity, an expansion of our understanding of the complex pathogenesis of the muscle‐liver‐adipose tissue axis in cirrhosis and evidence to support management recommendations for nutrition, exercise and pharmacological therapies.